These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 16042715)

  • 1. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
    Rini BI; Sosman JA; Motzer RJ
    BJU Int; 2005 Aug; 96(3):286-90. PubMed ID: 16042715
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
    Rini BI
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1753-60. PubMed ID: 17181489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy in renal cell carcinoma.
    Vakkalanka BK; Rini BI
    Curr Opin Urol; 2008 Sep; 18(5):481-7. PubMed ID: 18670271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major treatment improvements encourage kidney cancer researchers to seek further gains.
    Tuma RS
    J Natl Cancer Inst; 2008 Sep; 100(17):1202-3. PubMed ID: 18728277
    [No Abstract]   [Full Text] [Related]  

  • 5. Trials probe new agents for kidney cancer.
    Hampton T
    JAMA; 2006 Jul; 296(2):155-7. PubMed ID: 16835411
    [No Abstract]   [Full Text] [Related]  

  • 6. Present state of target therapy for disseminated renal cell carcinoma.
    Waalkes S; Kramer M; Herrmann TR; Schrader AJ; Kuczyk MA; Merseburger AS
    Immunotherapy; 2010 May; 2(3):393-8. PubMed ID: 20635903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapies in metastatic renal cancer in 2009.
    Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A
    BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapies for kidney cancer in urologic practice.
    Haas NB; Uzzo RG
    Urol Oncol; 2007; 25(5):420-32. PubMed ID: 17826664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy for metastatic renal cell carcinoma.
    Motzer RJ; Bukowski RM
    J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Golshayan AR; George S; Heng DY; Elson P; Wood LS; Mekhail TM; Garcia JA; Aydin H; Zhou M; Bukowski RM; Rini BI
    J Clin Oncol; 2009 Jan; 27(2):235-41. PubMed ID: 19064974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
    Rini BI
    Cancer; 2009 May; 115(10 Suppl):2306-12. PubMed ID: 19402073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
    Rini BI
    Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on targeted therapy in metastatic renal cell carcinoma.
    Lombardi G; Zustovich F; Donach M; Dalla Palma M; Nicoletto O; Pastorelli D
    Urol Oncol; 2012; 30(3):240-6. PubMed ID: 20456985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renal cell carcinoma].
    Obara W; Fujioka T
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1482-7. PubMed ID: 18799901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
    Kibble A; Shumoogam J
    IDrugs; 2007 Aug; 10(8):509-12. PubMed ID: 17665319
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
    Pouessel D; Culine S
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1761-7. PubMed ID: 17181490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular targeted therapy for renal cell carcinoma].
    Kakehi Y
    Rinsho Ketsueki; 2008 Aug; 49(8):622-5. PubMed ID: 18800611
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.